142 related articles for article (PubMed ID: 33590445)
1. HCV Viral Load Greater Than 1000 IU/ml at Time of Virologic Failure in Direct-Acting Antiviral-Treated Patients.
Morgan JR; Savinkina A; Pires Dos Santos AG; Xue Z; Shilton S; Linas B
Adv Ther; 2021 Mar; 38(3):1690-1700. PubMed ID: 33590445
[TBL] [Abstract][Full Text] [Related]
2. Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set.
Morgan JR; Marsh E; Savinkina A; Shilton S; Shadaker S; Tsertsvadze T; Kamkamidze G; Alkhazashvili M; Morgan T; Belperio P; Backus L; Doss W; Esmat G; Hassany M; Elsharkawy A; Elakel W; Mehrez M; Foster GR; Wose Kinge C; Chew KW; Chasela CS; Sanne IM; Thanung YM; Loarec A; Aslam K; Balkan S; Easterbrook PJ; Linas BP
J Viral Hepat; 2022 Jun; 29(6):474-486. PubMed ID: 35278339
[TBL] [Abstract][Full Text] [Related]
3. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C Virus RNA Levels Following Virologic Failure With Direct-acting Antivirals: Implications for Lower Sensitivity Diagnostic Assays.
Harrington PR; Komatsu TE; Sun H; Naeger LK
Clin Infect Dis; 2020 Jan; 70(2):327-330. PubMed ID: 31075159
[TBL] [Abstract][Full Text] [Related]
5. Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.
Sarrazin C; Isakov V; Svarovskaia ES; Hedskog C; Martin R; Chodavarapu K; Brainard DM; Miller MD; Mo H; Molina JM; Sulkowski MS
Clin Infect Dis; 2017 Jan; 64(1):44-52. PubMed ID: 27737953
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV.
Liu CJ; Chuang WL; Sheen IS; Wang HY; Chen CY; Tseng KC; Chang TT; Massetto B; Yang JC; Yun C; Knox SJ; Osinusi A; Camus G; Jiang D; Brainard DM; McHutchison JG; Hu TH; Hsu YC; Lo GH; Chu CJ; Chen JJ; Peng CY; Chien RN; Chen PJ
Gastroenterology; 2018 Mar; 154(4):989-997. PubMed ID: 29174546
[TBL] [Abstract][Full Text] [Related]
7. HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin.
Laufer N; Bolcic F; Rolón MJ; Martinez A; Reynoso R; Pérez H; Salomón H; Cahn P; Quarleri J
Antiviral Res; 2011 Apr; 90(1):92-7. PubMed ID: 21376083
[TBL] [Abstract][Full Text] [Related]
8. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
Naganuma A; Chayama K; Notsumata K; Gane E; Foster GR; Wyles D; Kwo P; Crown E; Bhagat A; Mensa FJ; Otani T; Larsen L; Burroughs M; Kumada H
J Gastroenterol; 2019 Aug; 54(8):752-761. PubMed ID: 30868245
[TBL] [Abstract][Full Text] [Related]
9. Spontaneous Clearance After Relapse Following Direct-Acting Antiviral Treatment for Chronic HCV Infection.
Kuriry H; Casey J; Krassenburg L; La D; Kuczynski M; Shah H; Janssen HLA; Hansen BE; Feld JJ
Clin Gastroenterol Hepatol; 2021 Nov; 19(11):2398-2406.e1. PubMed ID: 32629131
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and monitoring of HCV infection using the cobas
Yao JD; Young S; Heilek GM; Marino E; Paxinos EE; Marins EG; Valsamakis A
J Clin Virol; 2018 May; 102():63-69. PubMed ID: 29518694
[TBL] [Abstract][Full Text] [Related]
11. Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant.
Yoshida EM; Kwo P; Agarwal K; Duvoux C; Durand F; Peck-Radosavljevic M; Lilly L; Willems B; Vargas H; Kumar P; Brown RS; Horsmans Y; De-Oertel S; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault N; Rizzetto M; Müllhaupt B
Ann Hepatol; 2017; 16(3):375-381. PubMed ID: 28425407
[TBL] [Abstract][Full Text] [Related]
12. Boceprevir plus peginterferon α-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.
Gordon SC; Reddy KR; Jacobson IM; Poordad F; Bronowicki JP; Bacon B; Buti M; Hu KQ; Pedicone LD; Burroughs M; Brass CA; Albrecht JK; Lawitz EJ
J Clin Gastroenterol; 2014; 48(5):435-43. PubMed ID: 24177376
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.
Vermehren J; Aghemo A; Falconer K; Susser S; Lunghi G; Zeuzem S; Colombo M; Weiland O; Sarrazin C
J Hepatol; 2014 May; 60(5):913-9. PubMed ID: 24424305
[TBL] [Abstract][Full Text] [Related]
14. Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.
Johnson K; Green PK; Ioannou GN
J Viral Hepat; 2017 Nov; 24(11):966-975. PubMed ID: 28585416
[TBL] [Abstract][Full Text] [Related]
15. Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV).
Walker DR; Pedrosa MC; Manthena SR; Patel N; Marx SE
Adv Ther; 2015 Nov; 32(11):1117-27. PubMed ID: 26538232
[TBL] [Abstract][Full Text] [Related]
16. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of molecular parameters for routine assessment of viremia in patients with chronic hepatitis C who are undergoing antiviral therapy.
Kessler HH; Pierer K; Santner BI; Vellimedu SK; Stelzl E; Marth E; Fickert P; Stauber RE
J Hum Virol; 1998; 1(5):314-9. PubMed ID: 10195258
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the efficacy of antiviral therapy for hepatitis C virus infection by an ultrasensitive RT-PCR assay.
Kinai E; Hanabusa H; Kato S
J Med Virol; 2007 Aug; 79(8):1113-9. PubMed ID: 17596840
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam.
Nguyen DT; Tran TTT; Nghiem NM; Le PT; Vo QM; Day J; Rahman M; Le HM
PLoS One; 2020; 15(5):e0233446. PubMed ID: 32433676
[TBL] [Abstract][Full Text] [Related]
20. Eight-week ledipasvir/sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million: Single center, real world effectiveness and safety.
Latt NL; Yanny BT; Gharibian D; Gevorkyan R; Sahota AK
World J Gastroenterol; 2017 Jul; 23(26):4759-4766. PubMed ID: 28765697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
